SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• SAB Biotherapeutics received a “Moderate Buy” consensus rating from 11 analysts: nine buys, one hold and one sell. The average 12-month price target is $12.00, well above the reported share price of $3.72.
• Recent analyst actions were broadly positive, including upgraded or initiated price targets ranging from $11 to $16; Chardan Capital raised its target to the highest level of $16.
• Institutional ownership remains limited at 7.82%, while the company reported quarterly EPS of -$0.28, in line with estimates. Analysts expect a full-year loss of approximately $1.17 per share.

SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) has been given an average rating of "Moderate Buy" by the eleven ratings firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $12.00.

A number of brokerages have recently commented on SABS. Citigroup began coverage on shares of SAB Biotherapeutics in a report on Friday, May 22nd. They set a "buy" rating and a $11.00 price target for the company. Zacks Research upgraded SAB Biotherapeutics from a "strong sell" rating to a "hold" rating in a report on Monday, May 11th. Rodman & Renshaw reiterated a "buy" rating and issued a $13.00 target price on shares of SAB Biotherapeutics in a research note on Monday, May 11th. Leerink Partners raised their price target on SAB Biotherapeutics from $7.00 to $12.00 and gave the stock an "outperform" rating in a research note on Monday, June 15th. Finally, Chardan Capital lifted their price target on SAB Biotherapeutics from $14.00 to $16.00 and gave the company a "buy" rating in a report on Wednesday, June 17th.

Hedge Funds Weigh In On SAB Biotherapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. PNC Financial Services Group Inc. purchased a new position in shares of SAB Biotherapeutics in the 1st quarter worth $29,000. ADAR1 Capital Management LLC acquired a new stake in SAB Biotherapeutics during the third quarter worth about $30,000. Dimensional Fund Advisors LP purchased a new position in shares of SAB Biotherapeutics in the 3rd quarter worth about $32,000. State of Wyoming acquired a new position in shares of SAB Biotherapeutics in the 4th quarter valued at about $34,000. Finally, Virtu Financial LLC purchased a new stake in shares of SAB Biotherapeutics during the 3rd quarter worth about $40,000. Institutional investors and hedge funds own 7.82% of the company's stock.

SAB Biotherapeutics Stock Performance

SAB Biotherapeutics stock opened at $3.72 on Friday. SAB Biotherapeutics has a fifty-two week low of $1.85 and a fifty-two week high of $5.15. The company has a market capitalization of $338.48 million, a price-to-earnings ratio of -2.86 and a beta of 0.53. The stock has a fifty day moving average of $3.74 and a two-hundred day moving average of $3.77. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.22 and a current ratio of 9.22.

SAB Biotherapeutics (NASDAQ:SABS - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.28). On average, analysts anticipate that SAB Biotherapeutics will post -1.17 EPS for the current fiscal year.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company's proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company's lead programs are directed primarily at infectious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source